Tag Archives: Alethia Young

Ascendis Pharma (ASND) Received its Third Buy in a Row

After Wedbush and J.P. Morgan gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Alethia Young reiterated a Buy rating on Ascendis Pharma today and set a price

Cantor Fitzgerald Keeps a Buy Rating on Xencor Inc (XNCR)

Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Xencor Inc (XNCR – Research Report) today and set a price target of $40. The company’s shares opened today at $32.50. Young commented: “. We reiterate our Overweight rating and

Cantor Fitzgerald Sticks to Its Hold Rating for Amgen Inc (AMGN)

Cantor Fitzgerald analyst Alethia Young reiterated a Hold rating on Amgen Inc (AMGN – Research Report) today and set a price target of $221. The company’s shares closed on Friday at $189.98. Young wrote: “. We Reiterate our Neutral rating

Analysts Offer Insights on Healthcare Companies: TG Therapeutics (NASDAQ: TGTX) and Rhythm Pharmaceuticals Inc (NASDAQ: RYTM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TG Therapeutics (TGTX – Research Report) and Rhythm Pharmaceuticals Inc (RYTM – Research Report) with bullish sentiments. TG Therapeutics (TGTX) TG Therapeutics

Biogen Inc (BIIB) Gets a Hold Rating from Cantor Fitzgerald

In a report released today, Alethia Young from Cantor Fitzgerald reiterated a Hold rating on Biogen Inc (BIIB – Research Report), with a price target of $250. The company’s shares opened today at $232.94, close to its 52-week low of

Biogen Inc (BIIB) Gets a Buy Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst Alethia Young maintained a Buy rating on Biogen Inc (BIIB – Research Report) today and set a price target of $400. The company’s shares closed yesterday at $320.59. Young observed: “We think Biogen’s base business in MS